Form 4: Inovio Pharmaceuticals Director Wendy Yarno Reports Stock Option and Restricted Stock Unit Grants

Director Wendy Yarno reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Summary

• On May 21, 2024, Wendy Yarno, a director of Inovio Pharmaceuticals, reported the acquisition of 2,917 common stock options and 2,167 restricted stock units (RSUs).
• The options have an exercise price of $10.99 and vest 100% on May 21, 2025, expiring on May 21, 2034.
• The RSUs also vest 100% on May 21, 2025, and each unit represents a contingent right to receive one share of common stock.
• These grants were made under the 2023 Omnibus Incentive Plan, following the issuer's non-employee director compensation policy.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard compensation practice. It's neither particularly positive nor negative from an investment perspective.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to director compensation, which is a common practice in publicly traded companies to incentivize and retain board members. The specifics of the plan are not detailed enough to compare to industry standards.

Stakeholder Impact

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates